A local biopharmaceutical company looking to better understand and treat neurodegenerative diseases has landed some new funding.
Chicago-based Vanqua Bio raised nearly $45 million in new funding, according to a recent filing with the U.S. Securities and Exchange Commission. There were 12 participants in the offering, according to the filing.
A Vanqua Bio spokesperson confirmed to Chicago Inno Friday that it was an externally-led Series B extension round.
Founded in 2019, Vanqua Bio is focused on discovering and developing next-generation medicines focused on neurodegenerative diseases like Parkinson's disease, Gaucher disease, Alzheimer's disease and amyotrophic lateral sclerosis.
Jim Sullivan is CEO of Vanqua Bio.
The company moved to a new office in Fulton Labs after closing $85 million in Series B financing in 2021, relocating from Lincoln Park.
That initial Series B financing round was led by Omega Funds.
